Using the immune system to improve treatment for Hodgkin lymphoma
Targeting GPNMB in Hodgkin lymphoma
Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies
Understanding the molecular makeup of low grade glioma and DIPG
Molecular pathophysiology of histone G34R mutated childhood brain tumours: towards the development of novel targeted therapies
Improving our understanding of lymphoma in children with immune deficiency
Histopathology of lymphomas in children with primary immune deficiency
Investigating a newly discovered gene to improve our understanding of Wilms tumour
Epigenetic deregulation of splicing in childhood renal malignancies
Understanding the order of genetic changes that lead to Wilms tumour to improve treatment
Ordering of driver mutations in bilateral Wilms’ tumour
Understanding the biology of malignant rhabdoid tumours to develop targeted treatments
Improved therapeutic targeting in malignant rhabdoid tumours using discovery proteomics analysis
Understanding genetic changes in neuroblastoma cells to pave the way for targeted treatments
Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities
Understanding what goes wrong in cells that leads to malignant rhabdoid tumours
Unravelling the impact of SMARCB1 loss on the chromatin landscape in malignant rhabdoid tumor to identify novel therapeutic opportunities